StockNews.com Lowers Surgery Partners (NASDAQ:SGRY) to Sell
Surgery Partners (NASDAQ:SGRY – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
A number of other brokerages have also issued reports on SGRY. Benchmark reaffirmed a “buy” rating and set a $50.00 target price on shares of Surgery Partners in a research report on Thursday, October 12th. TD Cowen raised Surgery Partners from a “market perform” rating to an “outperform” rating and lowered their price objective for the company from $39.00 to $35.00 in a report on Tuesday, November 14th. TheStreet raised Surgery Partners from a “d+” rating to a “c-” rating in a report on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $43.00 price objective on shares of Surgery Partners in a report on Thursday, September 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Surgery Partners currently has an average rating of “Moderate Buy” and an average target price of $45.13.
Check Out Our Latest Stock Report on SGRY
Surgery Partners Stock Down 4.8 %
Shares of NASDAQ SGRY traded down $1.69 during midday trading on Tuesday, reaching $33.82. 1,012,961 shares of the company’s stock were exchanged, compared to its average volume of 730,548. Surgery Partners has a 52-week low of $22.05 and a 52-week high of $45.79. The stock has a market capitalization of $4.28 billion, a PE ratio of -105.69 and a beta of 2.86. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.61 and a current ratio of 1.75. The business’s fifty day moving average price is $27.84 and its two-hundred day moving average price is $34.09.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last announced its earnings results on Tuesday, November 7th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.05. Surgery Partners had a positive return on equity of 2.70% and a negative net margin of 1.26%. The business had revenue of $674.10 million for the quarter, compared to analyst estimates of $670.74 million. Analysts forecast that Surgery Partners will post 0.73 EPS for the current year.
Hedge Funds Weigh In On Surgery Partners
Institutional investors have recently made changes to their positions in the stock. Chase Investment Counsel Corp bought a new position in shares of Surgery Partners during the second quarter valued at approximately $2,338,000. Bank of New York Mellon Corp grew its holdings in shares of Surgery Partners by 2.0% during the first quarter. Bank of New York Mellon Corp now owns 236,244 shares of the company’s stock valued at $8,143,000 after purchasing an additional 4,739 shares during the last quarter. FORA Capital LLC bought a new position in shares of Surgery Partners during the first quarter valued at approximately $263,000. Premier Fund Managers Ltd bought a new position in shares of Surgery Partners during the second quarter valued at approximately $1,015,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Surgery Partners by 10.9% during the second quarter. Charles Schwab Investment Management Inc. now owns 514,828 shares of the company’s stock worth $23,162,000 after buying an additional 50,583 shares during the period.
About Surgery Partners (Get Free Report)
Surgery Partners, Inc, through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Surgery Partners, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Surgery Partners wasn’t on the list.
While Surgery Partners currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Which stocks are likely to thrive in today’s challenging market? Click the link below and we’ll send you MarketBeat’s list of ten stocks that will drive in any economic environment.
Original: MarketBeat News Feed: StockNews.com Lowers Surgery Partners (NASDAQ:SGRY) to Sell